Brain tumors: New therapy surprisingly successful

March 06, 2009

The combination of two drugs produces a critical improvement in the treatment of certain brain tumours. This has been demonstrated by researchers at Bonn University working in co-operation with German and Swiss colleagues in a current study. They treated 39 patients who had been diagnosed with a so-called gliablastoma. The patients survived on average 23 months; with the standard therapy the mean would have been 14.6 months. Glioblastomas are the most aggressive and the commonest brain tumours. Left untreated, they prove fatal within just a few weeks. The study has been published in the Journal of Clinical Oncology (doi: 10.1200/JCO.2008.19.2195).

Even today, glioblastomas are untreatable - something which even the new combination therapy cannot change. Nevertheless, Professor Dr. Ulrich Herrlinger of Bonn University's Schwerpunkt Klinische Neuroonkologie speaks of an outstanding success: "This unusually manifest extension of the survival time has surprised even us. Our results offer the opportunity to improve our grip on this aggressive form of cancer. Now, further investigations involving a larger number of patients are needed to optimise this therapy. Planning for this is already in hand in Bonn".

Up to now, doctors have treated glioblastomas using radiotherapy with concomitant chemotherapy. The "gold standard" for this for the last few years has been the active agent temozolomide. This is still celebrated as the most important breakthrough in the treatment of glioblastomas. The researchers combined this preparation with the drug lomustine. At the same time, the patients were given radiotherapy. The 39 patients thus treated survived the tumour for an average of 23.1 months. With the standard therapy, this time is over one third shorter. Seven patients even survived for over four years.

Genes decide the Success of the Therapy

It would appear that certain changes in the genotype are critical for the success of this therapy. "With eleven participants in the study, the information of one gene had been subjected to a characteristic modification", Ulrich Herrlinger declares. "These patients survived on average a good 34 months. With the other patients, these drugs appeared to bring no apparent advantage vis-à-vis pure radiotherapy - at least, not in the dosage we tested. It is possible that a simple gene test could decide for whom a concomitant chemotherapy might be of benefit". One disadvantage of the new method are the side-effects. However, these mostly occur during the several months of the treatment phase. "After that they normally disappear completely, and the patients have no further complaints about them", Herrlinger stresses.

Working in co-operation with the Life&Brain-Zentrum in Bonn, the search is now on for more compatible, more effective, drugs. "Amongst other things, we now want to use cell cultures from original tumours to study precisely what the preparations we used in the study really effect", Dr. Martin Glas, one of the authors of the study, declares.

University of Bonn

---

---

	Medifocus Guidebook on: Glioblastoma by Medifocus.com Inc. (Author), Elliot Jacob PhD. (Editor) The MediFocus Guidebook on Glioblastoma is the most comprehensive, up-to-date source of information available. You will get answers to your questions, including risk factors of Glioblastoma, standard and alternative treatment options, leading doctors, hospitals and medical centers that specialize in Glioblastoma, results of the latest clinical trials, support groups and additional resources, and promising new treatments on the horizon. This one of a kind Guidebook offers answers to your critical health questions including the latest treatments, clinical trials, and expert research; high quality, professional level information you can trust and understand culled from the latest peer-reviewed journals; and a unique resource to find leading experts, institutions, and support organizations...
	Tumors of the Central Nervous System, Volume 1: Gliomas: Glioblastoma (Part 1) by M. A. Hayat (Editor) The most recent developments in diagnostic and therapeutic aspects of Gliomas (Glioblastoma) in the brain are presented. The importance of personalized medicine and clinical validation for targeted therapy are discussed. The identification of various types of biomarkers is included. The identification and validation of brain cancer (glioblastoma) genes are discussed. Role of cancer stem cells in the initiation, progression, and persistence of malignant gliomas is explained. The use of surgical resection, chemotherapy (e.g., temozolomide), immunotherapy, and radiotherapy for malignant glioblastoma are pointed out. Standard (established) as well as newer imaging modalities (proton magnetic resonance spectroscopy) are discussed.
	Glioblastoma Multiforme by James Markert (Author), Vincent T. DeVita Jr. (Author), Steven A. Rosenberg (Author), Samuel Hellman (Author) This Book Provides Basic Researchers And Clinicians With A Contemporary Review Of The Epidemiology, Diagnosis, And Treatment Of Glioblastoma Multiforme, The Most Common And Most Deadly Type Of Brain Tumor. Expert Malignant Glioma Researchers And Clinicians Provide State-Of-The-Art Chapters On Important Topics Such As Molecular Genetic Classification Of Glioblastoma, Surgical Management, Stem Cell Therapy, Chemotherapy, Angiogenesis, And More.
	Tumors of the Central Nervous System, Volume 2: Gliomas: Glioblastoma (Part 2) by M.A. Hayat (Editor) Advantages and limitations of biomarkers in gliomagenesis are described. Molecular subtypes of gliomas are detailed. The role played by TP53 gene mutation in the deadliest brain tumor, glioblastoma multiforme, is pointed out. The role of mutations of IDH1 and IDH2, and isocitrate dehydrogenases in malignant gliomas are presented. Metabolic differences in different regions of the glioma tumor are clarified. Various types of imaging modalities, including PET and SPECT, to diagnose gliomas in general and glioblastoma in particular in patients are explained in detail. Both low-grade and high-grade gliomas are discussed. Conventional as well as fluorescent-guided resection techniques for high-grade, recurrent malignant gliomas are detailed. Impact of resection extent on outcomes in patients...
	Glioblastoma:: Molecular Mechanisms of Pathogenesis and Current Therapeutic Strategies by Swapan K. Ray (Editor) Glioblastoma is the most malignant brain tumor that still remains incurable. It is such a deadly disease that patients do not survive more than a few months after diagnosis. Our understanding of the histopathology and molecular mechanisms of formation of glioblastoma is rapidly advancing so as to provide us clues for devising rational therapeutic strategies for treatment of this malignancy. It is important that we continue to improve our knowledge about the pathogenesis of this devastating disease and explore new areas to find successful therapeutic strategies. Various approaches such as sophisticated imaging techniques, improved surgical procedures, ground-breaking strategies for radiotherapy, chemotherapy, immunotherapy, chemoimmunotherapy, and photodynamic therapy are being used for...
	A Statistic of One: My Walk With Glioblastoma Multiforme by Stephen Hatrak (Author) A Statistic of One: My Walk with Glioblastoma Multiforme traces Stephen Hatrak's life from his diagnosis of glioblastoma multiforme, the deadliest of malignant brain tumors, to the present. He chronicles the trials and tribulations he faced and the losses he suffered along his journey. Faith and inner strength are formidable allies in overcoming any tragedy in one's life, and they played vital roles in his struggle. He was told from the start that the he might have twelve months to live; even so, he defi ed the odds and, six years later, is telling his own story. Despite the dire statistics associated with a diagnosis of glioblastoma, there are several stories of long-term survival; these stories gave him hope that this cancer could be tamed. To overcome this challenge in his life, he had...
	Glioblastoma: Risk Factors, Diagnosis and Treatment Options (Cancer Etiology, Diagnosis and Treatment) by Marcelo F. Bezerra (Editor), Claudio R. Alves (Editor)
	21st Century Adult Cancer Sourcebook: Adult Brain Tumors - Primary Malignant Tumors, Glioma, Astrocytoma, Meningioma, Oligodendroglioma, Ependymoma, Glioblastoma by Progressive Management Authoritative information and practical advice from the nation's cancer experts about adult brain tumors includes official medical data on signs, symptoms, treatment options, surgery, radiation, drugs, chemotherapy, staging, biology, prognosis, and survival, with a complete glossary of technical medical terms and current references. Starting with the basics, and advancing to detailed patient-oriented and physician-quality information, this comprehensive in-depth compilation gives empowered patients, families, caregivers, nurses, and physicians the knowledge they need to understand the diagnosis and treatment of brain cancer - covering gliomas, astrocytomas, meningiomas, oligodendrogliomas, ependymomas, glioblastomas, and many others. Comprehensive data on clinical trials...
	What You Need to Know About Glioblastoma Cancer - It's Your Life, Live It! by Cancer Group Institute As an Oncology Nurse. I had only one protocol in mind while writing this 195 page book. That was to show you the most successful cancer treatments available today for Glioblastoma Cancer. To that end, you won't find a better warrior in the war on cancer than reading this book. We are honored to inform you that many leading hospitals use our books in their medical library to be used by physicians. They are Harvard University, Columbia, NYU, UCLA, Johns Hopkins, MD Anderson Cancer Center Orlando, Tift Regional Cancer Center, Instituto Oncologia Moderna, Puerto Rico plus many others. It is critical to get prompt diagnosis and proper treatment for glioblastoma cancer, this can literally make the difference between life and death. Understanding your options will give you...
	Glioblastoma: Webster's Timeline History, 1948 - 2007 by Icon Group International (Author) Webster's bibliographic and event-based timelines are comprehensive in scope, covering virtually all topics, geographic locations and people. They do so from a linguistic point of view, and in the case of this book, the focus is on "Glioblastoma," including when used in literature (e.g. all authors that might have Glioblastoma in their name). As such, this book represents the largest compilation of timeline events associated with Glioblastoma when it is used in proper noun form. Webster's timelines cover bibliographic citations, patented inventions, as well as non-conventional and alternative meanings which capture ambiguities in usage. These furthermore cover all parts of speech (possessive, institutional usage, geographic usage) and contexts, including pop culture, the arts, social...